Home › Research › Mild cognitive impairment
Clinical aspects of melatonin intervention in Alzheimer's disease progression
Cardinali DP, Furio AM, Brusco LI.. Current neuropharmacology, 2010-09-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsible for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. Half of severely ill AD patients develop chronobiological day-night rhythm disturbances like an agitated behavior during the evening hours (so-called "sundowning"). Melatonin replacement has been shown effective to treat sundowning and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez for articles including clinical trials and published up to 15 January 2010. Search terms were "Alzheimer" and "melatonin". Full publications were obtained and references were checked for additional material where appropriate. Only clinical studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate melatonin as a useful ad-on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.
What this study adds
Evidence grade: High
This review of clinical studies found that melatonin replacement has been shown effective to treat sundowning and other sleep-wake disorders in Alzheimer's disease patients, and it postulates melatonin as a useful add-on therapeutic tool in mild cognitive impairment. For Alzheimer's disease, it states that larger randomized controlled trials are necessary before effectiveness can be established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cardinali, D. P., Furio, A. M., & Brusco, L. I. (2010). Clinical aspects of melatonin intervention in Alzheimer's disease progression. Current neuropharmacology. https://doi.org/10.2174/157015910792246209
Vancouver
Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Current neuropharmacology. 2010. doi:10.2174/157015910792246209. PMID: 21358972.
BibTeX
@article{cardinali2010-21358972,
author = {Cardinali, D. P. and Furio, A. M. and Brusco, L. I.},
title = {{Clinical aspects of melatonin intervention in Alzheimer's disease progression}},
journal = {Current neuropharmacology},
year = {2010},
doi = {10.2174/157015910792246209},
pmid = {21358972},
url = {https://doi.org/10.2174/157015910792246209}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Search terms were "Alzheimer" and "melatonin".
- Full publications were obtained and references were checked for additional material where appropriate.
- Only clinical studies with empirical treatment data were reviewed.
- The analysis of published evidence made it possible to postulate melatonin as a useful ad-on therapeutic tool in MCI.
- In the case of AD, larger randomized controlled trials are necessary to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated.
Why it matters
This review of clinical studies found that melatonin replacement has been shown effective to treat sundowning and other sleep-wake disorders in Alzheimer's disease patients, and it postulates melatonin as a useful add-on therapeutic tool in mild cognitive impairment. For Alzheimer's disease, it states that larger randomized controlled trials are necessary before effectiveness can be established.
Study details
- Evidence strengthHigh
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current neuropharmacology) |
| Journal's citation record | 1 / 4 | Current Neuropharmacology: journal h-index 141 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 204 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 11.3 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 3 / 6 | Cited 5.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Luis Ignacio Brusco: h-index 26 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad de Buenos Aires: institution h-index 523 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21358972) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2174/157015910792246209
- PubMed: 21358972
- Original source →
- Free full text: Current Neuropharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment from nearby years
Also in Mild cognitive impairment
76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.